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Abstract 
A simple, precise and accurate method has been developed for simultaneous estimation of Ambroxol 
hydrochloride and Levocetirizine dihydrochloride. The proposed RP-HPLC method utilises Enable 
C18 G column (250 x 4.6mm, 5µm), mobile phase consisting of Phosphate buffer pH 3.0: Methanol 
in the ratio of 20:80 (v/v) and UV detection at 236nm using a photodiode array detector.The stability 
indicating capability of the method was proven by subjecting the drugs to stress conditions such as 
alkaline and acid hydrolysis, oxidation, photolysis, thermal degradation as per ich guidelines and 
resolution of the degradation products formed therein.The described method was linear over a range 
of 15 – 45 µg/mL for ambroxol hydrochloride and 1 – 3 µg/mL for levocetirizine dihydrochloride 
respectively. The method validation data showed excellent results for accuracy, precision, linearity, 
specificity, limit of detection, limit of quantification and robustness. The present method can be 
successfully used for routine quality control and stability studies. 
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1. Introduction 
Ambroxol hydrochloride (ABH) [1] chemically 
known as trans-4-[(2-Amino-3,5-dibromo benzyl) 
amino] cyclo hexanol hydrochloride is an active 
N-desmethyl metabolite of the mucolytic, 
bromhexine. Its mucolytic activity by which it 
facilitates breakdown of acid 
mucopolysaccharide fibres in the mucous making 
it thinner and less viscous and, therefore, easy for 
expectoration. It stimulates production of 
pulmonary surfactant, a substance found to play a 
major role in the lung host defence mechanism, 
thereby further protecting against lung 
inflammation and infection. 
Levocetirizine dihydrochloride (LEVC) [2] 
chemically known as (2-(4-[(R)-(4-Chlorophenyl) 
(phenyl) methyl] piperazin-1-yl)ethoxy) acetic 
acid dihydrochloride, the (R) enantiomer of 
cetirizine, is a potent and selective antagonist of 
peripheral H1-receptors. It has high affinity for 
human H1- receptors. 
 
 
Ambroxol hydrochloride 
 
 
 
 
 
 
 
Levocetirizine dihydrochloride 
 
From literature survey it was found that many 
methods had been reported for determination of 
ambroxol hydrochloride [3-8] and levocetirizine 
dihydrochloride [9-12] individually and in 
combination [13] with other drugs. In this present 
research work, it was proposed to develop and 
validate a stability indicating HPLC method for 
simultaneous estimation of Ambroxol 
hydrochloride and Levocetirizine dihydrochloride 
in marketed dosage formulations. 
 
2. Materials and methods 
2.1 Instrumentation: The high pressure liquid 
chromatographic (HPLC) system used was of 
model SHIMADZU UFLC-2000 Prominance 
LC-20AD SPDM 20A Binary Gradient System 
equipped with Rheodyne injector and PDA 
detector controlled by LC solutions (version 1.25) 
software. A column Enable C-18 G Column 
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(250mmx 4.6mm, 5µm) was used as a stationary 
phase.  
2.2 Materials: Ambroxol hydrochloride was 
obtained as a gift sample from Hetero pharma, 
Hyd, India, Levocetirizine dihydrochloride was 
obtained as a gift sample from Metro Chem API 
Pvt. Ltd, Hyd, Sodium dihydrogen phosphate, 
HPLC grade methanol manufactured by Merck 
was procured from commercial source. High 
purity deionised water was obtained from 
[Millipore, Milli-Q] purification system. Relent-
OD capsules (ambroxol hydrochloride 75mg and 
levocetirizine dihydrochloride 5mg) 
manufactured by Dr. Reddy’s Laboratories, Hyd 
were purchased from local market. 
 
2.3 Methods 
2.3.1 Selection of Wavelength: The wavelength 
of maximum absorption for ambroxol 
hydrochloride 248nm and levocetirizine 
dihydrochloride at 230nm. A single wavelength 
has selected for estimation of ambroxol 
hydrochloride and levocetirizine dihydrochloride 
as 236nm as both the peaks have the significant 
response. Overlay spectrum of ambroxol 
hydrochloride and levocetirizine dihydrochloride 
given in fig 1. 
2.3.2 Preparation of mobile phase: Sodium 
dihydrogen orthophosphate buffer (NaH2PO4) 
pH 3.0 was prepared by dissolving 15.61 gm of 
Sodium dihydrogen orthophosphate (NaH2PO4) 
in 1000 mL of water to get a concentration of 
0.1M. Then it was adjusted to pH 3 with ortho 
phosphoric acid. The mobile phase was prepared 
in the ratio of 20:80 v/v (Sodium dihydrogen 
orthophosphate buffer pH 3.0: Methanol) filtered, 
degassed and sonicated for 10 min. 
2.3.3. Preparation of Standard solutions: 
Standard stock solutions were prepared by 
dissolving 75 mg of ambroxol hydrochloride and 
5 mg of levocetirizine dihydrochloride in 100 mL 
of mobile phase (stock I) and then 4 mL of the 
above solution was further diluted to 100 mL 
with the same mobile phase, to get a 
concentration of 30µg/mL for ambroxol 
hydrochloride and 2µg/mL for levocetirizine 
dihydrochloride respectively (stock II). A typical 
chromatogram is given in Figure 2.  
2.3.4. Procedure for calibration curve:Five 
standard calibration solutions of ambroxol 
hydrochloride and levocetirizine dihydrochloride 
having concentration in the range of 15-45µg/mL 
and 1-3µg/mL respectively were prepared by 
diluting the stock I solution with mobile phase. 
(Table 5 & Fig 3 & 4) 
2.3.5. Estimation of ambroxol hydrochloride 
and levocetirizine dihydrochloride in capsule 
formulation: Contents from 20 capsules were 
emptied; the powder equivalent to 75 mg of 
ambroxol hydrochloride and 5mg of 
levocetirizine dihydrochloride was accurately 
weighed and transfered into clean, dry 100mL 
volumetric flask. The powder was first dissolved 
in few mL of mobile phase by sonication, the 
volume was made up to 100mL and then filtered 
through a Whatmann filter to obtain the 
concentration 750µg/mL and 50µg/mL for 
ambroxol hydrochloride and levocetirizine 
dihydrochloride respectively. From the above 
stock, 10mL were transferred into a 100mL 
volumetric flask and volume made up to 100mL 
with the mobile phase to get the concentration of 
75µg/mL for ambroxol hydrochloride and 5µg/mL 
for levocetirizine dihydrochloride respectively. 20 
µL solution of the working sample solutions were 
injected repeatedly into the chromatograph, at a 
flow rate of 1 ml/min and detection at 236 nm and 
the % assay was calculated. (Table 1) 
2.3.6. System Suitability Tests: System 
suitability was verified by injecting working 
standard solution of 30µg/mL of ambroxol 
hydrochloride and 2µg/mL of levocetirizine 
dihydrochloride. Various parameters such as 
HETP, number of theoretical plates, tailing factor 
and resolution between the peaks of ambroxol 
hydrochloride and levocetirizine dihydrochloride 
were obtained. (Table 2) 
2.4. Validation parameters [14]: The HPLC 
method was validated in terms of accuracy, 
precision, LOD, LOQ, linearity, range and 
robustness as per ICH guidelines. 
2.4.1. Accuracy: This parameter is performed to 
determine the closeness of test results with that of 
the true value which is expressed as % recovery. 
These studies were performed at three different 
levels (50%, 100% and 150%) and the % 
recovery of ambroxol hydrochloride and 
levocetirizine dihydrochloride was calculated. 
(Table 3) 
2.4.2. Precision: The precision (system, method) 
of the proposed method was evaluated by 
carrying out six independent assays of test 
sample. RSD (%) of six assay values obtained 
was calculated. The intermediate precision was 
carried out by analyzing the sample in different 
days. (Table 4)  
2.4.3. Specificity: Specificity of the method was 
evaluated by injecting the blank, working 
standard and stressed samples into the 
chromatograph to check the co-elution, if any, at 
the retention time of ambroxol hydrochloride peak 
Research Article                                                                             G. V. S. Kumar et al /2012 
 
36 
 
and levocetirizine dihydrochloride peak. (Fig 5 & 
6) 
2.4.4. Limit of Detection and Limit of 
Quantitation: The limit of detection (LOD) and 
the limit of quantitation (LOQ) for ambroxol 
hydrochloride and levocetirizine dihydrochloride 
were determined from standard deviation of the 
response and the slope. (Table 3)   
LOD= σ/S X 3.3 
LOQ= σ/S X 10 
2.4.5. Robustness: The robustness of the method 
was determined as a measure of the analytical 
method capability to be unaffected by small 
variations in method parameters. The different 
variations such as variation in flow rate by ± 0.2 
ml/minute, variation in wavelength by ± 2 nm. At 
these changed conditions, the standard solutions 
were injected. The amounts of ambroxol 
hydrochloride and levocetirizine dihydrochloride 
were calculated (% assay) in each varied 
condition. (Table 6) 
2.4.6. Forced degradation study: To confirm 
the stability indicating nature of the analytical 
method, forced degradation of ambroxol 
hydrochloride and levocetirizine dihydrochloride 
was carried out under acid/base hydrolytic, 
oxidative, photolytic and thermal stress 
conditions as per ICH recommended test 
conditions [15].  
The drugs were subjected to acid hydrolysis by 
using 0.1N hydrochloric acid for 6 hrs; base 
hydrolysis by using 0.1N sodium hydroxide 
solution for 6hrs; oxidation by using 3%v/v 
solution of hydrogen peroxide for 6hrs; thermal 
stress in a controlled- temperature oven at 60oC 
for 48hrs and photolytic stress using UV lamp for 
48hrs. (Fig. 7 & 8) 
 
3. Results and Discussion 
3.1 Method development: Several mobile phase 
compositions were tried to resolve the peaks of 
ambroxol hydrochloride, levocetirizine 
dihydrochloride and degraded components. The 
optimum mobile phase containing methanol–
sodium dihydrogen phosphate buffer 80:20 (v/v) 
was selected because it could resolve the peaks of 
ambroxol hydrochloride (RT = 3.4 ± 0.02) and 
levocetirizine dihydrochloride (RT = 4.7 ± 0.03) 
with a resolution factor of 6.6. The pH was 
adjusted to 3.0 ± 0.02 with orthophosphoric acid. 
Quantification was achieved with UV detection at 
236 nm on the basis of peak area. A typical 
HPLC chromatogram obtained during 
simultaneous estimation of ambroxol 
hydrochloride and levocetirizine dihydrochloride. 
(Fig. 2) 
3.2 Method validation: The proposed method 
was found to be accurate as the percentage 
recoveries at three levels 103.93%, 102.14%, 
103.84 for ABH and 104%, 99.19%, 102.2% for 
LEVC respectively which were found to be 
within the limits of acceptance criteria (90-
110%). For precision and intermediate precision 
% RSD of ABH and LEVC were within 2.0% 
thus confirm good precision of the analytical 
method development. The method found to be 
specific as there is no interference of the 
degraded components with the standard drugs. 
The LOD and LOQ of ABH and LEVC were 
found to be 3ng/mL, 9ng/mL and 0.05ng/mL, 
0.15ng/mL respectively. The calibration plot for 
the method was linear over the concentration 
range of 15-45µg/mL for ABH and 1-3µg/mL for 
LEVC respectively. The correlation coefficients 
(r2) were 0.998 for ABH and LEVC respectively. 
Robustness of the method was performed by 
making deliberate changes in flow rate and wave 
length and it was by calculating established % 
RSD values and was within acceptance criteria 
range of 2.0%.  
3.3 Forced Degradation: Forced degradation 
studies were carried out for the simultaneous 
estimation of ambroxol hydrochloride and 
levocetirizine dihydrochloride in acidic/alkaline 
hydrolysis, oxidation, thermal and photolytic 
stress. The peaks of the degradation components 
were well resolved from the peaks of main 
component and the drug components passed the 
purity test. Results of forced degradation study 
depicit that degradents appeared during oxidation 
stress study at retention time of 2.8min for 
ambroxol hydrochloride and 4.4min for 
levocetirizine dihydrochloride respectively where 
as during the alkali hydrolysis LEVC showed 
degradation at retention time of 4.4min.  
 
4. Conclusion 
A simple, precise and accurate method was 
developed for the quantitative estimation of 
ambroxol hydrochloride and levocetirizine 
dihydrochloride in bulk drug and marketed 
formulation without any interference from the 
excipients. The method is very simple and 
specific as both the peaks were well separated 
from their impurities and degraded components. 
The method has been found to be better than 
previously reported methods, because of use of a 
less economical and readily available mobile 
phase and lack of extraction procedures which 
makes the method especially suitable for routine 
quality control analysis work. 
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Table 1: Analysis of formulation 
 
Drug Labelled amount(mg) Amount found %Label claim 
ABH 75 75.55 100.93 
LEVC 5 4.97 99.38 
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Table 2: System Suitability Data of ABH and LEVC 
 
Compound Retention 
time 
Tailing factor Asymmetry Theoretical 
plate 
Resolution
ABH 3.46 1.49 0.75 6412.44  
6.61 LEVC 4.75 1.38 1 7833.83 
 
Table 3: Recovery data of ABH and LEVC 
 
Drugs Levels Mean recovery ±SD % RSD 
 
ABH 
L1 103.42% 0.54 0.52 
L2 101.78% 0.46 0.45 
L3 103.27% 0.51 0.49 
 
LEVC 
L1 103.71% 0.48 0.46 
L2 99.75% 0.50 0.50 
L3 101.8% 0.42 0.42 
     (N=3) 
Table 4: Intermediate precision data of ABH and LEVC 
 
 
Compound 
Intra-day precision Inter-day precision 
% of Label % RSD % of Label % RSD 
ABH 100.15 0.55 99.48 0.65 
LEVC 102.5 0.58 101.8 0.7 
       (N=6) 
Table 5: Linearity data for ABH and LEVC 
 
Linearity (n=5) ABH LEVC 
Range 15-45µg/mL 1-3µg/Ml 
Mean ‘r2’ value 0.998 0.998 
Regression equation Y=13152X – 40621 Y= 52277 X- 1274.5 
 
Table 6: Robustness data of ABH and LEVC 
 
 
Changing Factor 
 
Level 
ABH (n=3), Mean % assay  
(% RSD) 
LEVC (n=3), Mean % 
assay (% RSD) 
 
Flow rate 
0.9 Ml 98.66% (0.92%) 99.18% (0.83%) 
1.1 mL 99.09% (0.95%) 99.78% (0.94%) 
 
Wavelength 
231 99.2% (1.11%) 99.02% (0.92%) 
241 98.94% (0.95%) 99.34% (0.91%) 
 
Fig 1: Overlay Spectrum of Ambroxol hydrochloride and Levocetirizine dihydrochloride 
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Fig 2: Chromatogram for retention time of Ambroxol hydrochloride anLevocetirizine 
dihydrochloride in combination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3: Calibration curve of ABH  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4: Calibration curve of LEVC 
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Fig No.5: Chromatogram for specificity (Peak purity profile of ABH) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig No.6: Chromatogram for specificity (peak purity profile of LEVC) 
 
Fig 7: Chromatogram of ABH and LEVC in alkaline condition at 6th hr 
 
Fig 8: Chromatogram of ABH and LEVC in oxidation condition at 6th hr 
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